Libtayo

Cemiplimab, the active ingredient in Libtayo, is a monoclonal antibody (PD‑1 inhibitor) presented as an intravenous solution for infusion for intravenous use. It treats advanced cutaneous squamous cell carcinoma, locally advanced basal cell carcinoma, and metastatic or locally advanced non‑small cell lung cancer in adult patients.

GNH USA supplies Libtayo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Libtayo is used in oncology to target the PD‑1 pathway in several advanced skin and lung cancers. - Advanced cutaneous squamous cell carcinoma: improves overall response and disease control in adult patients. - Locally advanced basal cell carcinoma: provides tumor shrinkage and disease stabilization when surgery is not feasible. - Metastatic or locally advanced non‑small cell lung cancer: enhances progression‑free survival and overall response in patients whose disease has progressed after prior therapy.

Cemiplimab may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Rash: skin redness or irritation. - Diarrhea: increased frequency or loose stools. - Nausea: sensation of queasiness or urge to vomit.

Serious or Rare Side Effects: - Immune‑mediated pneumonitis: inflammation of lung tissue that can impair breathing. - Hepatitis: liver inflammation that may elevate liver enzymes. - Severe infusion‑related reactions: anaphylaxis or hypotension occurring during administration.

When prescribing cemiplimab, clinicians should observe several safety considerations. - Monitor for immune‑related adverse events: assess organ function regularly. - Evaluate for pre‑existing autoimmune conditions: weigh risk of exacerbation. - Conduct baseline and periodic laboratory tests: liver enzymes, thyroid function, and renal parameters. - Advise patients on infection risk: counsel on signs of infection and need for prompt medical attention. - Avoid live vaccines during treatment: immunosuppression may reduce efficacy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cemiplimab can interact with other medicines, primarily affecting immune function or increasing toxicity.

Major Interactions (Avoid): - Concurrent use of other immune checkpoint inhibitors: may amplify immune‑related toxicity. - Systemic corticosteroids at high doses: can diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents (e.g., azathioprine, methotrexate): may reduce antitumor response, require monitoring. - Live attenuated vaccines: risk of infection, avoid during therapy. - Anticoagulants (e.g., warfarin): monitor for bleeding if immune‑mediated thrombocytopenia occurs.